C12N2795/00021

Enterococcus faecalis bacteriophage and uses thereof

Bacteriophages are provided that infect strains of Enterococcus faecalis, an opportunistic bacterial pathogen that causes human disease. Also provided are methods of treating Enterococcus faecalis by therapeutic administration of such bacteriophages.

Therapeutic bacteriophage compositions

The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.

Bacteriophage and methods of using

Bacteriophage are provided, and methods of making and using the bacteriophage also are provided.

HIGHLY ORDERED PHAGE STRUCTURES AND USES THEREOF FOR STEM CELL DIFFERENTIATION
20220049218 · 2022-02-17 ·

A bacteriophage structure, a method of making the structure, and uses of the structure are described. The structure is a substrate with a surface having an ordered arrangement of parallel microridges thereon. Each microridge is composed of a plurality of nanoridges and has a longitudinal axis. Each nanoridge contains a bundle of phage nano fibers having longitudinal axes. The phage nanofibers in each nanoridge bundle are arranged in a substantially smectic alignment. The longitudinal axis of each microridge is perpendicular to the longitudinal axes of the phage nanofibers which make up the nanoridges of the microridge. The structure may be used as a growth surface for inducing differentiation of stem cells such as neural progenitor cells.

PHAGE THERAPY
20170319637 · 2017-11-09 ·

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Pseudomonas aeruginosa strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

Phage and use thereof in soil remediation

A phage and use thereof in soil remediation are disclosed. The phage φYSZPK has been deposited at the China Center for Type Culture Collection on Aug. 1, 2018 under Accession No. CCTCC M 2018516, and its taxonomic designation is Pseudomonas aeruginosa and Klebsiella phage φYSZPK. Biochar and the screened phage are combined and returned into contaminated soil to synergistically control and deeply track and inactivate transmission and spread of antibiotic resistance pathogenic bacteria and resistance genes in a soil-vegetable system. The combination of the biochar and the phage φYSZPK not only clearly improves the functional stability of microbial community in the soil-vegetable system, but also significantly alleviates the dissemination of the antibiotic resistance pathogenic bacteria in the soil-vegetable system to prevent secondary pollution, thereby providing a new solution for biological remediation and control of farmland soil contaminated by antibiotic resistance pathogenic bacteria in China.

Particle delivery via small-scale morphology materials for antibacterial applications

Disclosed herein is a particle delivery system comprising electrospun nanofiber comprised of coaxial fiber with a microfluidic core. Iron-doped apatite nanoparticles (IDANPs) have demonstrated a unique influence over phage killing of bacteria, whereby, IDANP-exposed bacterial cultures experience 2× the bacterial death as controls. IDANPs consist of hydroxyapatite (HA) doped with iron. HA is a mineral known to be biocompatible and analogous to the inorganic constituent of mammalian bone and teeth and has been approved by the Food and Drug Administration (FDA) for many applications in medicine and dentistry. Previous work has shown that for IDANPs to enhance antibacterial activity of phage to the greatest extent, bacterial cultures should be exposed to IDANPs for 1 hr prior to phage introduction. Biocompatible polymer materials which encase IDANPs and/or phage can be used to disseminate IDANPs and/or phage in a controlled manner into a physiological system for treatment of bacterial infection. When components of said materials contain micro- or nano-scale components, high surface-to-volume ratio for treatment delivery is garnered.

ANTIBACTERIAL AND PROTECTIVE BACTERIOPHAGE FORMULATIONS AND METHODS FOR MAKING AND USING THEM
20220162566 · 2022-05-26 ·

Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel. Provided are compositions and methods for treating, ameliorating and/or preventing a condition comprising an abnormal, disrupted or pathological mucosal surface or mucus-covered epithelium, or a condition caused, modified or effected by an abnormal, disrupted or pathological microbiotia, wherein optionally the infection or condition comprises a diarrhea, a colitis, obesity, diabetes, autism, a cystic fibrosis, a dysentery, a gastrointestinal infection, a gastrointestinal inflammation, a gastrointestinal dysbiosis, a gastrointestinal upset, a lung infection, a bacterial infection, a viral infection, a secondary infection, an inflammation, a mucus hypersecretion, or a dysbiosis.

Devices and methods for detecting microorganisms using recombinant reproduction-deficient indicator bacteriophage

Disclosed herein are compositions, methods, kits and systems for rapid detection of microorganisms using a reproduction-deficient indicator bacteriophage. The specificity of such reproduction-deficient indicator bacteriophage for binding and infecting particular microorganisms of interest allows targeted and sensitive detection of a microorganism of interest.

Production of lytic phages

The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.